Latest Content

Dr. Maurie Markman discusses how AI could support primary care doctors and specialists caring for patients with cancer while keeping physicians at the center.

A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.

She was diagnosed with stage 4 primary mediastinal B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma that starts in the center of the chest, at 29.

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

Dr. Maureen McEvoy explains breast cancer surgery options, reconstruction, recovery and how to close gaps in access to care.

For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.

A cancer survivor reflects on losing her hair during chemotherapy, the emotional impact of hair loss and what growing it back taught her about healing, identity and life.

After a lung cancer diagnosis, one Bronx writer reflects on faith, survivorship and learning that healing isn't a finish line, but a daily journey.

Dr. David DiBardino explains how intratumoral therapy is being studied to deliver treatment directly into tumors and potentially enhance radiation in patients with locally advanced non-small cell lung cancer.

See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.